83379 | Outcomes and Management of Hypoattenuating Leaflet Thickening and Clinical Valve Thrombosis post-TAVR

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Hypoattenuating Leaflet Thickening (HALT) post-TAVR (n=81). Intervention: Management strategies (e.g., oral anticoagulation). Primary outcome: Characterize real-world management strategies.

Chloé Kharsa; Aneesh Dhore Patil; Mangesh Kritya; Saliha Erdem; Karl Abou Zeid; Aidan Atkins; Charishma Nallapati; Joe Aoun; William Zoghbi; Michael Reardon; Nadeen Faza; Stephen Little; Neal Kleiman; Marvin Atkins

doi:10.1016/j.shj.2026.101000

June 1, 2026Structural HeartOpen Access

83379 | Outcomes and Management of Hypoattenuating Leaflet Thickening and Clinical Valve Thrombosis post-TAVR

View Full Paper

Ask AI

Bookmark

Share

Key Points

To characterize real-world management strategies and assess long-term clinical outcomes in patients diagnosed with hypoattenuating leaflet thickening (HALT) and clinical valve thrombosis following transcatheter aortic valve replacement (TAVR).
Retrospective cohort study of N=81 patients diagnosed with post-TAVR HALT between 2019 and 2024.
Evaluated imaging characteristics, management choices, and clinical outcomes over a median follow-up of 43 months (IQR: 19–76).
HALT was detected incidentally in 53.1% and presented as clinical valve thrombosis in 44.4%, with moderate-to-severe thickening (Grade ≥3) occurring in 42.6% and reduced leaflet motion in 49.4%.
Post-diagnosis management consisted of oral anticoagulation in 59.0% (33.3% apixaban, 17.9% warfarin), no change in management in 23.1%, and valve reintervention in 6.4%.
During follow-up, all-cause mortality reached 18.5%, heart failure hospitalization occurred in 21.0%, stroke in 11.1%, bleeding in 11.1%, and valve reintervention in 9.9%.

Study Design

Type

Observational (n=81)

Structured PICO

P

Population

81 patients (mean age 75.2 years, 46.9% female) with hypoattenuating leaflet thickening identified after TAVR, followed for a median of 43 months.

E

Exposure

Real-world management strategies (including oral anticoagulation in 59.0% of patients).

O

Outcome

Characterize real-world management strategies.

Limitations

Retrospective design
Absence of a standardized treatment strategy

Implication

Real-world management of HALT post-TAVR is highly variable, with most patients receiving oral anticoagulation, highlighting the need for standardized treatment strategies and prospective studies.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kharsa et al. (2026) conducted an observational in Hypoattenuating Leaflet Thickening (HALT) post-TAVR (n=81). Management strategies (e.g., oral anticoagulation) was evaluated on Characterize real-world management strategies.

synapsesocial.com/papers/6a3c2381d15afadd906fa3c6 https://doi.org/10.1016/j.shj.2026.101000

View Full Paper

Ask AI

Bookmark

Share

83379 | Outcomes and Management of Hypoattenuating Leaflet Thickening and Clinical Valve Thrombosis post-TAVR

Key Points

Study Design

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

83379 | Outcomes and Management of Hypoattenuating Leaflet Thickening and Clinical Valve Thrombosis post-TAVR

Key Points

Study Design

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Structural Heart

Keep reading

More related papers

More from Structural Heart